Mirum Pharmaceuticals, Inc.
MIRM
Hisse Senetlerindeki Sıralama
#3345
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Hisse Fiyatı
$80.17
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$5.21B
Değişim (1 gün)
-2.69%
Değişim (1 yıl)
9.03%
Ülke
US
Ticaret Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Mirum Pharmaceuticals, Inc. (MIRM) için EPS
June 2026 itibariyle EPS TTM: $-14.56
Mirum Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-14.56'dir. 2023 yılı sonunda, şirketin EPS'si $-4.00 idi; bu, 2022 yılındaki EPS olan $-4.01 ile önceki yıla göre azalma.
Mirum Pharmaceuticals, Inc. için 2018 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
